AWAlyssa T. Watanabe

Alyssa T. Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alyssa T. Watanabe has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial Intelligence–based Software for Breast Arterial Calcification Detection on Mammograms

    by Alyssa T Watanabe, Valerie Dib, Junhao Wang, Richard Mantey, William Daughton, Chi Yung Chim, Gregory Eckel, Caroline Moss, Vinay Goel, Nitesh Nerlekar

    Objective: The performance of a commercially available artificial intelligence (AI)–based software that detects breast arterial calcifications (BACs) on mammograms is presented. Methods: This retrospective study was exempt from IRB approval and adhered to the HIPAA regulations. Breast arterial calcification detection using AI was assessed in 253 patients who underwent 314 digital mammography (DM) examinations and 143 patients who underwent 277 digital breast tomosynthesis (DBT) examinations between October 2004 and September 2022. Artificial intelligence performance for binary BAC detection was compared with ground truth (GT) determined by the majority consensus of breast imaging radiologists. Area under the receiver operating curve (AUC), sensitivity, specificity, positive predictive value and negative predictive value (NPV), accuracy, and BAC prevalence rates of the AI algorithm were compared. Results: The case-level AUCs of AI were 0.96 (0.93-0.98) for DM and 0.95 (0.92-0.98) for DBT. Sensitivity, specificity, and accuracy were 87% (79%-93%), 92% (88%-96%), and 91% (87%-94%) for DM and 88% (80%-94%), 90% (84%-94%), and 89% (85%-92%) for DBT. Positive predictive value and NPV were 82% (72%-89%) and 95% (92%-97%) for DM and 84% (76%-90%) and 92% (88%-96%) for DBT, respectively. Results are 95% confidence intervals. Breast arterial calcification prevalence was similar for both AI and GT assessments. Conclusion: Breast AI software for detection of BAC presence on mammograms showed promising performance for both DM and DBT examinations. Artificial intelligence has potential to aid radiologists in detection and reporting of BAC on mammograms, which is a known cardiovascular risk marker specific to women.


  • Potential Impact of an Artificial Intelligence–based Mammography Triage Algorithm on Performance and Workload in a Population-based Screening Sample

    by Alyssa T Watanabe, Hoanh Vu, Chi Y Chim, Andrew W Litt, Tara Retson, Ray C Mayo

    To evaluate potential screening mammography performance and workload impact using a commercial artificial intelligence (AI)–based triage device in a population-based screening sample. In this retrospective study, a sample of 2129 women who underwent screening mammograms were evaluated. The performance of a commercial AI-based triage device was compared with radiologists’ reports, actual outcomes, and national benchmarks using commonly used mammography metrics. Up to 5 years of follow-up examination results were evaluated in cases to establish benignity. The algorithm sorted cases into groups of “suspicious” and “low suspicion.” A theoretical workload reduction was calculated by subtracting cases triaged as “low suspicion” from the sample. At the default 93% sensitivity setting, there was significant improvement (P <.05) in the following triage simulation mean performance measures compared with actual outcome: 45.5% improvement in recall rate (13.4% to 7.3%; 95% CI, 6.2-8.3), 119% improvement in positive predictive value (PPV) 1 (5.3% to 11.6%; 95% CI, 9.96-13.4), 28.5% improvement in PPV2 (24.6% to 31.6%; 95% CI, 24.8-39.1), 20% improvement in sensitivity (83.3% to 100%; 95% CI, 100-100), and 7.2% improvement in specificity (87.2% to 93.5%; 95% CI, 92.4-94.5). A theoretical 62.5% workload reduction was possible. At the ultrahigh 99% sensitivity setting, a theoretical 27% workload reduction was possible. No cancers were missed by the algorithm at either sensitivity. Artificial intelligence–based triage in this simulation demonstrated potential for significant improvement in mammography performance and predicted substantial theoretical workload reduction without any missed cancers.


  • Multicenter, Multivendor Validation of an FDA-approved Algorithm for Mammography Triage

    by Tara A Retson, Alyssa T Watanabe, Hoanh Vu, Chi Yung Chim

    Objective: Artificial intelligence (AI)–based triage algorithms may improve cancer detection and expedite radiologist workflow. To this end, the performance of a commercial AI-based triage algorithm on screening mammograms was evaluated across breast densities and lesion types. Methods: This retrospective, IRB-exempt, multicenter, multivendor study examined 1255 screening 4-view mammograms (400 positive and 855 negative studies). Images were anonymized by providing institutions and analyzed by a commercially available AI algorithm (cmTriage, CureMetrix, La Jolla, CA) that performed retrospective triage at the study level by flagging exams as “suspicious” or not. Sensitivities and specificities with confidence intervals were derived from area under the curve (AUC) calculations. Results: The algorithm demonstrated an AUC of 0.95 (95% CI: 0.94–0.96) for case identification. Area under the curve held across densities (0.95) and lesion types (masses: 0.94 [95% CI: 0.92–0.96] or microcalcifications: 0.97 [95% CI: 0.96–0.99]). The algorithm has a default sensitivity of 93% (95% CI: 95.6%–90.5%) with specificity of 76.3% (95% CI: 79.2%–73.4%). To evaluate real-world performance, a sensitivity of 86.9% (95% CI: 83.6%–90.2%) was tested, as observed for practicing radiologists by the Breast Cancer Surveillance Consortium (BCSC) study. The resulting specificity was 88.5% (95% CI: 86.4%–90.7%), similar to the BCSC specificity of 88.9%, indicating performance comparable to real-world results. Conclusion: When tested for lesion detection, an AI-based triage software can perform at the level of practicing radiologists. Drawing attention to suspicious exams may improve reader specificity and help streamline radiologist workflow, enabling faster turnaround times and improving care.


  • Open Access

    Improved Cancer Detection Using Artificial Intelligence: a Retrospective Evaluation of Missed Cancers on Mammography

    by Alyssa T. Watanabe, Vivian Lim, Hoanh X. Vu, Richard Chim, Eric Weise, Jenna Liu, William G. Bradley, Christopher E. Comstock

    To determine whether cmAssist™, an artificial intelligence-based computer-aided detection (AI-CAD) algorithm, can be used to improve radiologists’ sensitivity in breast cancer screening and detection. A blinded retrospective study was performed with a panel of seven radiologists using a cancer-enriched data set from 122 patients that included 90 false-negative mammograms obtained up to 5.8 years prior to diagnosis and 32 BIRADS 1 and 2 patients with a 2-year follow-up of negative diagnosis. The mammograms were performed between February 7, 2008 (earliest) and January 8, 2016 (latest), and were all originally interpreted as negative in conjunction with R2 ImageChecker CAD, version 10.0. In this study, the readers analyzed the 122 studies before and after review of cmAssist™, an AI-CAD software for mammography. The statistical significance of our findings was evaluated using Student’s t test and bootstrap statistical analysis. There was a substantial and significant improvement in radiologist accuracy with use of cmAssist, as demonstrated in the 7.2% increase in the area-under-the-curve (AUC) of the receiver operating characteristic (ROC) curve with two-sided p value < 0.01 for the reader group. All radiologists showed a significant improvement in their cancer detection rate (CDR) with the use of cmAssist (two-sided p value = 0.030, confidence interval = 95%). The readers detected between 25 and 71% (mean 51%) of the early cancers without assistance. With cmAssist, the overall reader CDR was 41 to 76% (mean 62%). The percentage increase in CDR for the reader panel was significant, ranging from 6 to 64% (mean 27%) with the use of cmAssist. There was less than 1% increase in the readers’ false-positive recalls with use of cmAssist. With the use of cmAssist TM, there was a substantial and statistically significant improvement in radiologists’ accuracy and sensitivity for detection of cancers that were originally missed. The percentage increase in CDR for the radiologists in the reader panel ranged from 6 to 64% (mean 27%) with the use of cmAssist, with negligible increase in false-positive recalls.